New drug targets Hard-to-Treat cancers with missing gene
NCT ID NCT07601243
First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times
Summary
This early-stage trial tests an oral drug called GS-2426 in people with advanced solid tumors that lack a gene called MTAP. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 174 adults whose cancer has not responded to standard treatments will take part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GS-2426 (oral drug)
- What this could lead to
- If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific genetic deletion (MTAP).
- What could go wrong
- This is an early Phase 1 trial focused on safety and dosing, not yet on effectiveness. The drug may not work or could cause side effects. Only people with a specific tumor type (MTAP-deleted) are eligible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
-
START Astera, LLC
RECRUITINGEast Brunswick, New Jersey, 08816, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
START San Antonio, LLC
RECRUITINGSan Antonio, Texas, 78229, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.